Search

In Stock

Buy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) Online

DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease, Asthma

MANUFACTURER: GlaxoSmithKline

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Pharmaceuticals and Medical Devices Agency (PMDA)

 

It is used for the management of chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by breathing difficulties, coughing, and wheezing. This medication is designed to provide comprehensive treatment for COPD by addressing various aspects of the disease.

$755.34

Clear
Compare

Description:

Trelegy Ellipta is a pharmaceutical medication that combines three active ingredients—fluticasone furoate, umeclidinium, and vilanterol—in a single inhaler. It is used for the management of chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by breathing difficulties, coughing, and wheezing. This medication is designed to provide comprehensive treatment for COPD by addressing various aspects of the disease.

Here is a detailed description of Trelegy Ellipta:

Active Ingredients:

  1. Fluticasone Furoate: Fluticasone furoate is a corticosteroid medication. It works by reducing inflammation in the airways, which can help to alleviate symptoms such as coughing and shortness of breath and reduce the risk of COPD exacerbations.
  2. Umeclidinium: Umeclidinium is an anticholinergic bronchodilator. It helps relax and widen the airways, making it easier for individuals with COPD to breathe by improving airflow and reducing symptoms like chest tightness and wheezing.
  3. Vilanterol: Vilanterol is a long-acting beta-agonist bronchodilator. It also helps to relax and open the air passages in the lungs, allowing for easier breathing and improved lung function.

Dosage Form: Trelegy Ellipta is available as a powder for inhalation in a special inhaler device called the Ellipta inhaler.

Indications: Trelegy Ellipta is indicated for the long-term maintenance treatment of COPD in adults. It is prescribed to help manage and control COPD symptoms and improve lung function.

Usage: The dosing and administration of Trelegy Ellipta are typically determined by a healthcare provider. It is usually taken once daily by inhaling the medication through the Ellipta inhaler. Patients should follow their healthcare provider’s instructions carefully to ensure proper usage.

Benefits: Trelegy Ellipta offers the advantage of combining three different types of medications in a single inhaler, simplifying the treatment regimen for COPD patients. By addressing both inflammation and bronchoconstriction, it can help improve lung function, reduce symptoms, and enhance the overall quality of life for individuals with COPD.

Precautions: Before starting Trelegy Ellipta, patients should consult with a healthcare provider. They should disclose any allergies, medical conditions, or other medications they are taking, as these factors can affect the safety and efficacy of the medication.

Side Effects: Like any medication, Trelegy Ellipta may cause side effects, which can vary from person to person. Common side effects may include headache, cough, or throat irritation. Serious side effects are rare but can include increased blood pressure, heart palpitations, and changes in blood glucose levels. Patients should promptly report any unusual or severe side effects to their healthcare provider.

In conclusion, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a combination medication used for the management of COPD in adults. It combines three active ingredients to provide comprehensive relief by reducing inflammation and relaxing the airways. Patients should use it as prescribed by their healthcare provider and be aware of potential side effects and precautions associated with its use.

Package

100/62.5/25 mcg fluticasone furoate, umeclidinium and vilanterol, 200/62.5/25 mcg fluticasone furoate, umeclidinium and vilanterol

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Yupelri (revefenacin) Online

(0 Reviews)
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease MANUFACTURER: Theravance Biopharma USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Yupelri is a pharmaceutical medication used to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by difficulty breathing, coughing, and wheezing.

Buy Tezspire (tezepelumab-ekko) Online

$6,696.25
(0 Reviews)
DISEASE INDICATIONS: Asthma MANUFACTURER: Amgen / AstraZeneca AB USAGE: Subcutaneous MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Tezspire (tezepelumab-ekko) is a prescription medication that belongs to the drug class of monoclonal antibodies. It is used to treat severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. Tezspire is the first and only biologic approved for severe asthma without phenotypic or biomarker limitations.

Buy Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) Online

From $39,106.10
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals Incorporated USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

Buy Orkambi (lumacaftor/ivacaftor) Online

From $10,806.14
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) This medication is designed to address the underlying cause of CF in individuals who have two copies of the F508del mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which is a common genetic mutation associated with CF.

Buy Symdeko (tezacaftor / ivacaftor) Online

$39,418.95
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) , Symdeko is indicated for the treatment of patients with CF who have specific genetic mutations that are responsive to these medications. This combination therapy addresses the underlying cause of CF by improving the function of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, which is often dysfunctional in CF patients.

Buy Kalydeco (ivacaftor) Online

From $7,241.59
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Kalydeco (ivacaftor) is a medication prescribed for individuals with cystic fibrosis (CF) who are 4 months of age and older and possess at least one CF gene mutation that responds to Kalydeco treatment.

Buy Clenbuterol Harasawa Online

$102.85
(0 Reviews)
DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS) MANUFACTURER: Harasawa USAGE: Oral MEDICINE APPROVED BY: Pharmaceuticals and Medical Devices Agency (PMDA) Clenbuterol, a medication employed in the management of individuals afflicted with bronchial asthma, chronic bronchitis, emphysema, acute bronchitis, or stress urinary incontinence, has diverse applications in the medical field. Notably, physicians occasionally opt for Clenbuterol's off-label use in the treatment of patients grappling with ALS (Amyotrophic Lateral Sclerosis). It's worth mentioning that Clenbuterol was previously recognized by its brand name, TONIL (clenbuterol).

Back to Top
Product has been added to your cart